|3rd December 2020||Franklin M Berger||6,534||Exercise of derivative||$4.00||$26,136.00|
|3rd December 2020||Franklin M Berger||2,184||Exercise of derivative||$3.81||$8,321.04|
|3rd December 2020||Franklin M Berger||6,773||Exercise of derivative||$4.67||$31,629.91|
|3rd December 2020||Franklin M Berger||25,000||Exercise of derivative||$3.23||$80,750.00|
|3rd December 2020||Franklin M Berger||1,716||Exercise of derivative||$4.00||$6,864.00|
|11th June 2020||Franklin M Berger||100,000||Open or private purchase||$5.50||$550,000.00|
|11th June 2020||Talent Investments Ltd Equal||1,454,545||Open or private purchase||$5.50||$7,999,997.50|
|4th February 2020||Christopher J. Kirk||38,461||Open or private purchase||$2.60||$99,998.60|
|4th February 2020||Venture Investments Ltd Morningside||3,800,000||Open or private purchase||$2.60||$9,880,000.00|
|4th February 2020||Franklin M Berger||120,846||Open or private purchase||$2.60||$314,199.60|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company. The firm specializes in the areas of protein degradation and protein secretion. Its product include KZR-616, an immunoproteasome inhibitor.